Financial Snapshot

Revenue
$212.1K
TTM
Gross Margin
-1726.95%
TTM
Net Earnings
-$46.25M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
8.57%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$4.449M
Q3 2024
Cash
Q3 2024
P/E
-0.1077
Nov 29, 2024 EST
Free Cash Flow
-$9.270M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $645.2K $933.7K $105.0K $0.00 $0.00 $0.00
YoY Change -30.9% 789.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $645.2K $933.7K $105.0K $0.00 $0.00 $0.00
Cost Of Revenue $756.8K $766.8K $77.98K
Gross Profit -$111.7K $166.9K $27.05K $0.00
Gross Profit Margin -17.31% 17.88% 25.75%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $18.88M $1.849M $36.92M $7.930M $5.700M $5.080M $210.0K
YoY Change 920.65% -94.99% 365.57% 39.12% 12.2% 2319.05%
% of Gross Profit 1107.89% 136485.66%
Research & Development $7.074M $7.268M $5.043M $940.0K $180.0K $530.0K $0.00
YoY Change -2.67% 44.13% 436.45% 422.22% -66.04%
% of Gross Profit 4353.81% 18641.85%
Depreciation & Amortization $542.6K $429.0K $476.2K $20.00K
YoY Change 26.48% -9.92% 2281.2%
% of Gross Profit 256.97% 1760.59%
Operating Expenses $25.95M $25.65M $41.96M $8.870M $5.880M $5.610M $210.0K
YoY Change 1.18% -38.88% 373.08% 50.85% 4.81% 2571.43%
Operating Profit -$26.06M -$25.48M -$41.93M -$8.870M
YoY Change 2.29% -39.24% 372.77%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense -$6.380M -$2.229M -$1.935M -$310.0K $0.00 -$80.00K
YoY Change 186.25% 15.15% 524.35% -100.0%
% of Operating Profit
Other Income/Expense, Net -$6.328M $2.170M $4.436M
YoY Change -391.64% -51.09%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$32.39M -$27.65M -$46.37M -$9.150M -$5.830M -$5.690M -$210.0K
YoY Change 17.15% -40.37% 406.79% 56.95% 2.46% 2609.52%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$32.70M -$27.65M -$46.37M -$9.150M -$5.830M -$5.690M -$210.0K
YoY Change 18.27% -40.37% 406.79% 56.95% 2.46% 2609.52%
Net Earnings / Revenue -5068.46% -2961.28% -44150.59%
Basic Earnings Per Share -$108.20 -$14.89 -$121.20
Diluted Earnings Per Share -$108.20 -$14.89 -$2.429M -$1.326M -$602.3K -$587.8K -$21.69K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $97.10K $2.769M $7.872M $10.50M $0.00 $120.0K $30.00K
YoY Change -96.49% -64.83% -25.03% -100.0% 300.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $217.4K $496.9K $460.1K $530.0K
YoY Change -56.25% 7.99% -13.19%
Inventory $745.5K $950.1K $494.7K
Prepaid Expenses
Receivables $408.3K $528.0K $89.84K
Other Receivables $5.445M $0.00 $500.0K
Total Short-Term Assets $6.913M $4.744M $9.417M $11.03M $0.00 $120.0K $30.00K
YoY Change 45.73% -49.63% -14.63% -100.0% 300.0%
Property, Plant & Equipment $4.099M $5.479M $6.364M $1.670M
YoY Change -25.2% -13.91% 281.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $22.38M $355.4K $379.3K $70.00K
YoY Change 6198.68% -6.3% 441.79%
Other Assets $11.17M $50.00K $289.5K $0.00 $120.0K $0.00
YoY Change 22247.54% -82.73% -100.0%
Total Long-Term Assets $37.67M $5.992M $7.247M $2.070M $120.0K $0.00 $0.00
YoY Change 528.63% -17.32% 250.11% 1625.0%
Total Assets $44.58M $10.74M $16.66M $13.10M $120.0K $120.0K $30.00K
YoY Change
Accounts Payable $8.555M $1.959M $1.576M $240.0K $1.850M $1.060M $10.00K
YoY Change 336.81% 24.31% 556.48% -87.03% 74.53% 10500.0%
Accrued Expenses $999.9K $1.087M $1.145M $390.0K $960.0K $430.0K $50.00K
YoY Change -7.98% -5.11% 193.62% -59.38% 123.26% 760.0%
Deferred Revenue
YoY Change
Short-Term Debt $16.03M $0.00 $0.00 $0.00 $170.0K $160.0K $0.00
YoY Change -100.0% 6.25%
Long-Term Debt Due $147.8K $410.0K $700.4K $590.0K
YoY Change -63.94% -41.47% 18.72%
Total Short-Term Liabilities $25.89M $3.644M $3.607M $1.230M $2.980M $1.650M $60.00K
YoY Change 610.53% 1.01% 193.27% -58.72% 80.61% 2650.0%
Long-Term Debt $0.00 $0.00 $110.0K $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $2.642M $1.885M $2.766M $860.0K $30.00K
YoY Change 40.13% -31.84% 221.62%
Total Long-Term Liabilities $2.642M $1.885M $2.876M $860.0K $0.00 $0.00 $30.00K
YoY Change 40.13% -34.45% 234.42% -100.0%
Total Liabilities $28.52M $5.529M $6.483M $2.090M $2.980M $1.650M $80.00K
YoY Change 415.87% -14.72% 210.2% -29.87% 80.61% 1962.5%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 302.4K shares 1.855M shares 381.8K shares
Diluted Shares Outstanding 302.4K shares 1.855M shares 381.8K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $4.982 Million

About Aditxt, Inc.

Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 47 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Industry: Pharmaceutical Preparations Peers: Acorda Therapeutics, Inc. Benitec Biopharma Inc. Panbela Therapeutics, Inc. Statera Biopharma, Inc. CONTRAFECT Corp CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Xenetic Biosciences, Inc. NAVIDEA BIOPHARMACEUTICALS, INC. Dogwood Therapeutics, Inc.